Immunotoxins

DBCAT000153Pharmacologic class

Semisynthetic conjugates of various toxic molecules, including RADIOACTIVE ISOTOPES and bacterial or plant toxins, with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; and ANTIGENS. The antitumor or antiviral immune substance carries the toxin to... A DrugBank category of 15 drugs. 5 of them are approved.

Also known as: Affinotoxins · Antibody Toxin Conjugates · Antibody Toxin Hybrids · Antibody-Toxin Conjugates · Antibody-Toxin Conjugates, Monoclonal
Drugs: Bivatuzumab mertansine
Brentuximab vedotin
Cantuzumab mertansine
Coltuximab ravtansine
Gemtuzumab ozogamicin
Inotuzumab ozogamicin
Lmb-7
Lorvotuzumab mertansine
Moxetumomab pasudotox
Naratuximab emtansine
ONCOLYSIN B
Trastuzumab emtansine
XMMME-001-RTA
XomaZyme-791
Zolimomab aritox

What you can answer from here — as of August 24, 2016

15DrugsEach linked to its full drug card

Listed above

12Drug targetsEvery drug–target pair in the class, with bond type

43Marketed productsAcross the regions we cover, with dosage forms and routes

3Routes of administrationHow the drugs in this class are given

Which targets do Immunotoxins share, and which companies have late-stage candidates in this class?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account